Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab vs High-Dose Interferon in Resected Mucosal Melanoma
NCT03178123Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in mucosal melanoma (MM), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2017; status: terminated.
02
Drugs
toripalimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03178123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178123.